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Introduction
Influenza vaccination is the primary strategy for prevention of 
influenza infection, with the United States Advisory Committee 
on Immunization Practices (ACIP) recommending vaccination 
for individuals ages 6 months and older [1, 2]. Influenza 
infection can vary from mild or even asymptomatic illness to 
severe community-acquired pneumonia (CAP) [3]. Although 
most individuals recover from influenza infection, young 
children, older adults, and individuals with other chronic 
medical conditions may experience more serious illness and 
increased mortality [4-6]. 
Due to rapid mutations and other variations in influenza viruses 
year to year around the world, annual vaccination is necessary 
to provide immunologic protection from infection. Even in the 
absence of direct matches between the circulating influenza 
viruses and the antigens included in the vaccine, it is thought 
that a reduction in severity may be conferred through the 
vaccination [7-9]. Due to these factors, it is of medical and 
public health interest to understand the effectiveness of the 
vaccine each season for prevention of various outcomes. 
Vaccine effectiveness, not be confused with vaccine efficacy, 
is a clinical approach to determining how effective a vaccine 
is in reducing a disease in a real-life population. Although 
there are several study designs to assess vaccine effectiveness, 
retrospective case-control analysis of vaccination rates are 
commonly employed. Vaccine efficacy is primarily measured 
in prospective, randomized clinical trials. These trials involve 
selected populations that may not be generalizable to the 
population at large [10]. 
Although many national and international investigators and 
organizations report annual estimates of influenza vaccine 
effectiveness for prevention of influenza infection in the 
community, few studies report estimates for the prevention of 
hospitalizations due to influenza-CAP, the most severe form of 
the infection [11-13]. 
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Abstract
Introduction: Influenza vaccination is the primary strategy for prevention of influenza infection. 
Influenza infection can vary from mild or even asymptomatic illness to severe community-acquired 
pneumonia (CAP). Although many national and international investigators and organizations report 
annual estimates of influenza vaccine effectiveness for prevention of influenza infection in the 
community, few studies report estimates for the prevention of hospitalizations due to influenza CAP, 
the most severe form of the infection. The objective of this study is to determine the effectiveness 
of the influenza vaccine for prevention of hospitalization in patients with influenza-associated CAP.
Methods: This was a test-negative study using data from the first two years of the University of 
Louisville Pneumonia Study, a prospective, observational study of all hospitalized patients with 
pneumonia in Louisville, Kentucky from 6/1/2014 – 5/31/2016. Univariate and multivariate logistic 
models were used to evaluate the association between vaccine status and influenza-associated/non-
influenza-associated CAP hospitalization. Unadjusted and adjusted vaccine effectiveness estimates 
were calculated.
Results: A total of 1951 hospitalized patients with CAP were included in the analysis, and 831 (43%) 
reported having received the influenza vaccination for the influenza season by the time they were 
hospitalized. A total of 152 (8%) cases of influenza-CAP were confirmed in the study population, with 
63 (8%) cases confirmed in vaccinated individuals. The unadjusted vaccine effectiveness was not 
significant, with a point estimate of 5% (95% CI: -33%, 32%). After adjusting for potential cofounders, 
vaccine effectiveness was also found to not be significant with a point estimate of 8% (95% CI: -30%, 
35%). 
Conclusions: In conclusion, we found that, over the 2014/2015 and 2015/2016 influenza seasons, 
influenza vaccine was not effective for prevention of hospitalization with CAP due to influenza. More 
effective vaccines are necessary to prevent the most serious forms of influenza.
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ORIGINAL RESEARCH
The objective of this study is to determine the effectiveness 
of the influenza vaccine for prevention of hospitalization in 
patients with influenza-CAP and to determine how well the 
estimated effectiveness in the general population estimates the 
effectiveness in hospitalized patients with CAP.
Methods
Study Design & Study Patients: This was a test-negative study 
using data from the first two years of the University of Louisville 
Pneumonia Study, a prospective, observational study of all 
hospitalized patients with pneumonia in Louisville, Kentucky 
from 6/1/2014 – 5/31/2016 [14].
Subjects: Patients were only eligible for inclusion in this analysis 
if they 1) were hospitalized during the influenza season in each 
study year (January, February, March, October, November, 
December), and 2) had a reverse-transcriptase polymerase 
chain reaction (RT-PCR) and/or rapid influenza diagnostic 
testing (RIDT) performed during hospitalization. Patients 
were considered vaccinated if they self-reported receiving any 
influenza vaccination for that influenza season prior to their 
hospitalization.
Study Definitions and Measurements: Community-
Acquired Pneumonia (CAP): A patient was defined as 
having CAP when the following 3 criteria were met: 1) presence 
of a new pulmonary infiltrate on chest radiograph and/or chest 
computed tomography scan at the time of hospitalization, 
defined by a attending radiologist’s reading; 2) at least 1 of 
the following: a) new cough or increased cough or sputum 
production, b) fever >37.8°C (100.0°F) or hypothermia <35.6°C 
(96.0°F), c) changes in leukocyte count (leukocytosis: >11,000 
cells/μL; left shift: >10% band forms/mL; or leukopenia: <4000 
cells/μL); and 3) no alternative diagnosis at the time of hospital 
discharge that justified the presence of criteria 1 and 2 [14].
Hospitalization with influenza-CAP: A hospitalized patient 
with CAP testing positive for an influenza virus of any subtype 
using Reverse Transcriptase-Polymerase Chain Reaction (RT-
PCR) or Rapid Influenza Diagnostic Testing (RIDT) during 
hospitalization.
Hospitalization with Non-Influenza-CAP: A hospitalized 
patient with CAP testing negative for an influenza virus of any 
subtype using RT-PCR or RIDT during hospitalization.
Influenza Vaccine Status: Influenza vaccine status for the 
influenza season of hospitalization was defined via self-report as 
documented in the medical record.
Confounding Variables: The following variables were 
considered as potentially confounding the relationship between 
vaccine status and hospitalization with CAP: age, race, sex, and 
history of the following social and medical factors: neoplastic 
disease, congestive heart failure (CHF), renal disease, diabetes, 
alcoholism, chronic obstructive pulmonary disease (COPD), 
human immunodeficiency virus (HIV), and current smoking 
status.
Statistical Analysis: Comparisons between those with and 
without influenza vaccination were made using descriptive 
statistics: frequencies with percentages as well as medians with 
interquartile ranges for categorical and continuous variables, 
respectively. Statistical associations between variables were 
made using Chi-Squared tests and Mann-Whitney U-tests. 
P-values of less than 0.05 were considered statistically 
significant. R version 3.4.3 (R Foundation, Vienna, Austria) was 
used for all analyses [15]. 
Unadjusted and adjusted vaccine effectiveness estimates 
were calculated. A crude Odds Ratio (cOR) evaluating the 
unadjusted association between vaccine status and influenza/
non-influenza-CAP hospitalization was calculated from a 2x2 
contingency table of observed influenza-CAP hospitalizations 
by reported vaccination status. The unadjusted estimate was 
calculated by the following equation, (1 – cOR) * 100 [16, 17].
To obtain adjusted vaccine effectiveness, a multivariable logistic 
regression model was created to control for confounding effects 
in the relationship between vaccine status and influenza/
non-influenza-CAP hospitalization. Based off of theoretical 
importance, the final model controlled for age, sex, race, 
neoplastic disease, CHF, renal disease, diabetes, alcoholism, 
COPD, HIV, and current smoking status. The adjusted odds 
ratio (aOR) was derived from this model and an adjusted 
vaccine effectiveness estimate was calculated using the following 
equation: (1 – aOR) * 100.
Post hoc sensitivity analysis included unadjusted and adjusted 
vaccine effectiveness for hospitalizations with no influenza-CAP 
coinfections, as well as sensitivity analysis for hospitalizations 
that did not utilize RIDT.
Human Subjects Protection: Participants in the primary 
University of Louisville Pneumonia Study provided their 
consent for inclusion in the vaccine recall ancillary study. 
Results
Characteristics of Vaccinated and Unvaccinated 
Hospitalized Patients with and Without Influenza-
Associated CAP
Table 1 outlines the characteristics of hospitalized patients 
with CAP by vaccine status. Hospitalized CAP patients who 
were vaccinated with the current year’s influenza vaccine were 
significantly less likely to be from a Black/African American 
racial background (16% vaccinated vs 22% unvaccinated, 
P=0.002), were older (69 years vs 63 years P<0.001), smoked 
less (26% vaccinated vs 36%, P<0.001) and were significantly 
more likely to have various comorbid conditions. 
A total of 1951 hospitalized patients with CAP were included 
in analysis, and 831 (43%) reported having received the 
influenza vaccination for the influenza season by the time 
they were hospitalized. A total of 152 (8%) cases of influenza-
CAP were confirmed in the study population, with 63 (8%) 
cases confirmed in vaccinated individuals. There were 13 CAP-
influenza hospitalizations with a bacterial coinfection. Four of 
these 13 coinfections were found in unvaccinated individuals.
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Table 1 Patients Characteristics (n=1951)
Influenza Vaccine Effectiveness for Prevention of 
Hospitalization due to Influenza-Associated CAP 
Table 2 outlines the observed 2x2 Contingency Table for the 
proportion of influenza-CAP hospitalization by vaccination 
status. The unadjusted vaccine effectiveness was not significant, 
with a point estimate of 5% (95% CI: [-33%, 32%]). After 
adjusting for potential cofounders, vaccine effectiveness was 
also not significant with a point estimate of 8% (95% CI: [-30%, 
35%]). 
 
Table 2 2x2 Contingency Table: Influenza-CAP Hospitalizations by 
Vaccination Status
Post Hoc Sensitivity Analysis
The presence of coinfection was unlikely to alter the effectiveness 
of the vaccine. This was confirmed by post hoc sensitivity 
analysis in which the 13 CAP-influenza infections were removed 
from analysis. With no adjustments, vaccine effectiveness 
in hospitalizations with no CAP-influenza coinfections was 
not significant and remained insignificant after adjusting for 
potential cofounders. The type of influenza test used was also 
considered for post hoc sensitivity analysis to control for the 
effect of false-negative RIDT. Only hospitalizations who received 
RT-PCR testing were included in this analysis. Unadjusted and 
adjusted estimates were not significant. Post hoc sensitivity 
analysis suggests that the influenza vaccine effectiveness in CAP 
hospitalizations is not significantly affected by influenza-CAP 
coinfections, or the type of influenza test conducted.
Discussion
This study suggests that the seasonal influenza vaccine may not 
be effective for preventing hospitalizations due to influenza-
CAP. One important clinical implication is that although 
vaccines may be a primary prevention strategy for some 
infections, they are not 100% effective. Populations at risk for 
severe disease or poor clinical outcomes, such as the young 
children and the elderly, may need to take increased measures to 
reduce the risk of influenza infection. As vaccination remains as 
the primary recommendation for prevention, clinicians should 
also recommend annual vaccinations and monitor vaccination 
status of all patients. 
Our data contradicts the results of other studies from similar 
years, and vaccine effectiveness reported by the CDC during 
the 2014-2015 and 2015-2016 flu seasons. The CDC reports, in 
reference to a 2015 study conducted by Zimmerman, R.K., et al. 
[18], an adjusted vaccine effectiveness of 19% (95% CI: [10% - 
27%]) during the 2014-2015 flu season. This is significantly 
higher than our suggested effectiveness in influenza-CAP 
hospitalizations. For the 2015-2016 flu season, the CDC 
reported an adjusted vaccine effectiveness from another of 48% 
(95% CI [41% - 55%]) [19], which is significantly higher than 
our suggested effectiveness in influenza-CAP hospitalizations. 
Similar to our study, vaccine effectiveness was calculated from 
the results of test-negative design from the same study years. 
However, conflicting results are likely due to different study 
populations. Reports from the CDC are based off of results from 
studies across all age groups, while our study is only specific to 
hospitalizations due to CAP.   
It is possible that, although we did not find the vaccine to be 
effective for the prevention of hospitalization due to influenza-
CAP, it may be effective for other outcomes or prevention of 
influenza infection. Previous vaccine studies have suggested 
potential benefits of influenza vaccination other than preventing 
CAP-hospitalization. In addition to reducing the risk of CAP-
hospitalizations, a 2005 cohort study of individuals 65 years 
and older reported a reduced risk of all-cause mortality before, 
during, and after flu seasons when comparing vaccinated and 
unvaccinated individuals [20]. Results from this study are 
likely due to the advantages in the study design, which were not 
obtainable in our study. Jackson, L.A., et al. (2006), rigorously 
followed members of a health maintenance organization 
(HMO), prospectively recording information on enrollment, 
immunizations, as well diagnosis in inpatient and outpatient 
settings, allowing for the control of multiple biases, and the 
assessment of multiple outcomes at different time periods.  
Our study does provide supporting evidence that vaccine 
effectiveness varies substantially from year to year and 
evidence that findings from other studies may not estimate 
the true effectiveness in hospitalizations from influenza-
CAP. It should also be noted that vaccine studies often differ 
in design and complexity, with no best standard or practice 
currently recognized. A strength of this study is the use of data 
from a population-based study, increasing the sample size and 
potentially increasing generalizability. Additionally, using a 
test-negative study design to estimate vaccine effectiveness 
offered a real-world view on how well the influenza vaccine 
reduced hospitalizations due to influenza-CAP and how well the 
target population was immunized. 
This study has several limitations. Although test-negative study 
designs are generally simple and less costly, they are subject to 
many forms of bias [10]. First, not all hospitalization records 
reported the use of PCR diagnostics for influenza, which is a 
standard for laboratory confirmation of influenza virus. Although 
readily available and able to provide quick results, previous 
studies have shown that the diagnostic accuracy of a RIDT 
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 Study Population Unvaccinated Vaccinated P-value
 Total No. = 1951 1120 831
Demographics
Male sex, Frequency(%) 496 (44) 367 (44) 0.994
Race: Black, Frequency(%) 241 (22) 131 (16) 0.002
Age, Median(IQR)* 63 (18) 69 (16) <0.001
Social and Medical History
Chronic obstructive pulmonary disease 492 (44) 409 (49) 0.023
Diabetes mellitus 326 (29) 296 (36) 0.003
Current smoker 402 (36) 218 (26) <0.001
Congestive heart failure 265 (24) 250 (30) 0.002
HIV disease 35 (3) 13 (2) 0.04
Stroke 106 (9) 93 (11) 0.242
Neoplastic disease 105 (9) 105 (13) 0.026
Renal disease 279 (25) 254 (31) 0.007
Obesity (BMI >= 30) 408 (36) 313 (38) 0.629
Severity of Disease on Admission
Need for intensive care 178 (16) 116 (14) 0.264
Altered mental status 163 (15) 116 (14) 0.76
Need for ventilatory support 133 (12) 98 (12) >0.999




  Unvaccinated Vaccinated 
Non-Influenza-CAP 1031 (A) 768 (B) 













Crude, Unadjusted Odds Ratio (𝒄𝒄𝒄𝒄𝒄𝒄)     = (𝐴𝐴/𝐶𝐶)/(𝐵𝐵/𝐷𝐷) 
                                                                         = (1031/89) / (768/63) 
                                                                         = 0.950272121 ≈ .95 
Crude, Unadjusted Vaccine Effectiveness     =	(1 − 𝑐𝑐𝑐𝑐𝑐𝑐) ∗ 100 
                                                                                = (1 −	 .95) ∗ 100 
                                                                                = 5% 
can vary across populations [21]. Therefore, patients testing 
negative on a RIDT and who did not receive a PCR test may have 
been misclassified into the non-influenza-CAP hospitalization 
group. It is also believed that for some vaccines, self-reported 
vaccination status may not match actual vaccine receipt [22] 
[23].  This would bias our results through misclassification of 
the predictor and outcome variables. Although influenza vaccine 
is recommended for individuals without contraindications over 
the age of 6 months in the United States, actual vaccine receipt 
is differentially distributed between individuals with different 
characteristics and geographies. This may introduce bias by the 
way of a form of confounding by indication, necessitating other 
study designs or analytical approaches. 
Another limitation is through the pooling of vaccine 
effectiveness estimates across multiple study years. It is possible 
that the vaccine may have been effective one year but not the 
next, or vice versa, leading to an overall estimate that suggested 
it was not effective. It is suggested that multi-season studies 
may be a more useful approach when trying to understand 
the effectiveness of repeat vaccination [24], which was not 
considered in this study. It is also unknown which vaccine route 
was obtained, potentially adding more bias to the study results. 
During the time of this study, individuals were still receiving 
Live-Attenuated Influenza Vaccine via nasal mist, which the 
ACIP advised against using during the 2016 – 2017 flu season 
due to identification of inferiority to other routes [25] . Further, 
the population under study is generally older. Currently, elderly 
individuals are recommended to receive high-dose influenza 
vaccine to counteract age-related immunosenescence [26, 
27]. We did not collect this data, which may result in some 
bias in our estimates. Finally, since we did not collect data on 
influenza subtypes, it is possible that the vaccine is effective for 
various influenza A or influenza B strains in the prevention of 
hospitalization for influenza-CAP.
Vaccine effectiveness estimates for various outcomes should 
continue to be studied on an annual basis. Prospective studies 
have the potential to evaluate other outcomes other than 
hospitalization or infection. Potential mechanisms of interaction 
may exist between vaccine uptake and outcomes such as severity 
of disease, time to clinical improvement, length of hospital stay, 
clinical failure, and short and long-term mortality. Additional 
analytical approaches to counteract confounding by indication, 
misclassification, and geographical variations in vaccine receipt 
should be enhanced and utilized in future large-scale vaccine 
effectiveness studies. 
In conclusion, we found that, over the 2014/2015 and 2015/2016 
influenza seasons, influenza vaccine was not effective for 
prevention of hospitalization with influenza-CAP. Development 
of novel vaccines that enhance effectiveness for various 
outcomes, and are effective across multiple seasons, are needed.
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